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Summary One hundred and fifty two patients with seminoma of the testis presenting to a regional centre
between 1970 and 1981 have been reviewed. One hundred and forty three of these patients were treated
primarily with radiotherapy. The actuarial survival of all 152 patients was 84.4% at 5 years and 83.3% at 10
years. The following factors significantly influenced survival: clinical stage; T-stage of the primary tumour;
date of first treatment. Patients treated after 1979 had a better prognosis than patients treated before 1973. A
group of patients with an actuarial survival of 100% at 5 years could be identified: they were in clinical stage
I after lymphography and had Tl primary tumours.
We could find no clear relationship between tumour size, duration of symptoms and clinical stage at
presentation.
We conclude that radiation therapy still has an important role to play in the management of seminoma of
the testis. We recommend prophylactic retroperitoneal irradiation for patients in clinical stage I, primary
treatment with radiotherapy for patients in clinical stages IIA and IIB, and primary treatment with
chemotherapy for patients in clinical stages IIC, III and IV.
Management policies for patients with germ-cell tumours
have been changing rapidly over the past few years. The
dramatic improvement in prognosis for nonseminomatous
germ-cell tumours has overshadowed the more subtle
developments in the management of seminomas. The
traditional approach to the treatment of seminomas has been
heavily based on radiotherapy, even for advanced disease.
Prophylactic radiotherapy, for example to the mediastinum
and supraclavicular fossa in patients with nodal disease
below the diaphragm, has been widely used. It is now
apparent that seminomas are as sensitive to cytotoxic chemo-
therapy as are the nonseminomatous tumours (Einhorn &
Williams, 1980; Ball et al., 1982; Schuette et al., 1985). This,
together with improvements in diagnostic imaging, and a
desire to minimize the morbidity of therapy has prompted
re-evaluation of treatment policies for seminoma of the testis
(Oliver et al., 1984).
In order to evaluate any new treatment policy it is
important to have adequate data on the results achieved by
the traditional policy. This applies not just to survival and
relapse-free survival but also to the identification of factors
which might affect prognosis. This review attempts to
provide such data.
Patients and methods
Patients
All patients referred to the Department of Clinical Oncology,
Western General Hospital, Edinburgh, with a diagnosis of
germ-cell tumour during the period 1970 to 1981 inclusive
have been reviewed. The department of Clinical Oncology is
a regional centre serving a defined population and the
observed number of referrals corresponds closely to the
known incidence in the population served by the department.
A total of 336 patients were referred. All tumours were
classified using the TTP classification (Thackray & Crane,
1976). There were 152 patients with primary seminomas of
the testis. Patients with malignant teratomas, mixed tumours
(malignant teratoma+seminoma) or extragonadal semi-
nomas have been excluded from consideration. The patients'
ages ranged from 19.2 to 74.61 years; median 35.62; mean
37.40. There were 85 (55.8%) patients with right sided
tumours and 67 (44.2%) patients with left sided tumours.
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The majority of patients 124/152 (81.5%) presented with
testicular swelling as their first symptom. A minority
presented with testicular pain: 29/152 (19.0%). The
combination of testicular pain and swelling occurred in
13/152 (8.5%). Testicular pain occurred at some time in the
clinical course in 39/152 (25.5%) of patients. Three patients
noted hardening of the testicle as their initial symptom.
Individual patients presented with the following symptoms:
groin pain; suprapubic pain; puffy eyelids; abdominal pain;
shrinkage of the testicle; haematospermia; backache.
Staging investigations changed during the period under
review. Before 1972 staging was based upon clinical
examination, chest X-ray (CXR) and i.v. urography (IVU);
lymphography became available in 1972 and thereafter a
total of 115 patients had lymphography as part of their
initial evaluation. Tumour markers, alpha foetoprotein
[AFP], the beta subunit of human chorionic gonadotrophin
[,BHCG], lactate dehydrogenase [LDH], were not routinely
measured until 1978.
All patients have been staged according to both the TNM
system (UICC, 1978) and the Royal Marsden Hospital
staging system (Peckham et al., 1981): information on T
stage was not available for all patients. The primary tumours
were staged as TI in 60 patients and as T2, T3 or T4 in 50
patients. The size of the primary tumour was estimated, if
possible, from clinical findings or from the pathologists'
report on the orchiectomy specimen. The primary tumour
volume was calculated using the formula 4/3rcr3: the value
for r being half the average tumour diameter in cm.
The distribution by clinical stage was: Stage 1 103 patients
(67.7%); Stage II 41 patients (26.9%); Stage III 3 patients
(2%); Stage IV 5 patients (3.3%). There was no significant
difference in stage grouping when patients under the age of
40 at diagnosis were compared with those over that age.
Treatment policy Management policies varied only slightly
during the period under review. Patients with Stage I disease
received megavoltage radiotherapy on 4MV or 6MV linear
accelerators. The majority received a central dose of
3000cGy in 20 fractions over 4 weeks using parallel opposed
fields. Both fields were treated daily, five days per week. The
fields extended from the T10/11 junction to the lower border
of the obturator foramina and were the shape of a truncated
pyramid. The position of the kidneys was defined using i.v.
urography, with the patient in the treatment position. The
kidneys were then carefully excluded from the radiation
field. The inguinal scar was included within the field of
irradiation and tissue equivalent bolus was applied to the
area of the scar. The contralateral testis was outwith the
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treated volume and a lead scrotal shield was also used.
Using this technique the dose to the remaining testis is
within the range 75-150cGy. If scrotal orchiectomy or trans-
scrotal biopsy had been performed then the whole scrotum
was included within the field.
All patients with Stage II disease received subdiaphrag-
matic irradiation using the fields described. In some patients
the involved nodes were treated with additional radiotherapy
using localized fields. Some patients received prophylactic
supradiaphragmatic radiotherapy. A central dose of
3000cGy in 20 daily fractions was given using parallel
opposed fields to a volume encompassing the mediastinum
and left supraclavicular fossa. Supradiaphragmatic radio-
therapy was not usually started until at least three weeks
after the completion of radiotherapy to the para-aortic
nodes.
Patients with Stage III or IV disease received indivi-
dualized therapy. Only three patients were treated with cis-
platinum since most of the patients were treated before this
drug was available.
Methods
The date of diagnosis has been defined as the date of the
surgical procedure which yielded the tissue from which the
diagnosis of seminoma was made: usually this was the date
of orchiectomy. Only one patient has been lost to follow up
within two years of treatment: he is assumed to have died
from disease. The mean follow-up is 6.25 years and the
median is 5.75 years. Lifetables, with logrank testing for
statistical significance, have been used to assess survival and
relapse free survival. Age corrections have not been applied.
Chi-square and t statistics, where appropriate, have also
been used.
Results
The actuarial survival for the whole group of 152 patients is
84.4% at 5 years and 83.3% at 10 years. No patient with
clinical Stage III or Stage IV disease survived for more than
five years. The actuarial survival for all patients with Stage I
disease is 95% at both 5 and 10 years. The survival for
patients with Stage II disease is 72% at 5 years and 66% at
10 years. The survival difference between Stage I and Stage
II tumours is statistically significant (P<0.01). The survival
curves for Stage I, IIA, IIB, IIC are shown in Figure 1.
Figure 2 shows the survival curve for the 60 patients with TI
primary tumours compared with the curve for the 50
patients whose primary tumours were T2, T3 or T4. The
survival with a TI primary was 92% at 5 and 10 years. The
survival for patients with primary tumours T> 1 was 79% at
5 years and 75% at 10 years. This difference is statistically
significant (P<0.02).
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Figure 1 Actuarial survival for all patients in clinical stages I
and II.
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Figure 2 Actuarial survival for the 60 patients with TI tumours
compared with the 50 patients with primary tumours T> 1.
P<0.02 (logrank).
Lymphography was performed in 78 patients who were
shown to have Stage I disease, their 5 and 10 year survival
rates were 96.11%. There were 38 patients with Ti primary
tumours and Stage I disease who had lymphography as part
of their initial staging. The 5 and 10 year actuarial survival
rate in this group is 100%. Only two of these patients
relapsed, secondary therapy was successful and they survive
disease-free. There were 24 patients with clinical stage I
disease who did not have lymphography. Their actuarial
survival at 5 and 10 years was 79.2%.
Seven patients with Stage I seminoma died; two relapsed
initially in lung and supra-diaphragmatic nodes; five relapsed
initially in mediastinal or supraclavicular nodes. A further
five patients with Stage I seminoma were successfuly treated
for relapse. One patient relapsed in the prostate; two
relapsed in lung; one relapsed in nodes above the diaphragm.
Ten patients with Stage II disease died from seminoma:
four with Stage IIA, and six with Stage IIB or IIC. Of the
patients in Stage IIA one had had prophylactic radiotherapy
above the diaphragm and three had not. The patient who
had been irradiated prophylactically relapsed in mediastinal
nodes. The sites of relapse in the three other patients were
brain, bone, and supraclavicular nodes. Of the patients with
Stage IIB or IIC disease two had prophylactic irradiation
above the diaphragm. Both patients initially relapsed in the
region that had been treated prophylactically. Of the four
patients who were treated by radiotherapy only to the nodes
below the diaphragm one died from uncontrolled intra-
abdominal disease, two died from liver metastases and one
died from uncontrolled disease above the diaphragm. One
patient who presented with Stage II seminoma relapsed in
lung and was successfully treated with thoracic irradiation.
There has been a definite improvement in the overall
prognosis for all treated patients during the study period.
The 5 year survival rate for patients treated before 1973 is
64.8%. The 5 year survival rate for patients treated after
1979 is 96.6% (P<0.01). The actuarial survival curves for
these two groups are shown in Figure 3.
Three patients have died from causes other than
seminoma. One patient died from unexplained
encephalopathy with no evidence of tumour. One patient
was treated for seminoma in 1974, in 1977 he developed
Hodgkin's disease and was treated with MOPP (mustine,
vincristine, procarbazine, prednisolone). He died in 1981 and
at post mortem had amyloidosis, rheumatoid disease and
alcoholic cirrhosis. There was no evidence of seminoma or
Hodgkin's disease. The third patient died from metastatic
teratoma: he had been treated for seminoma in 1973 and
developed a malignant teratoma of the opposite testis in
1978.
Three additional patients have had second primary
tumours of the testis (two seminomas; one malignant
teratoma). These three patients remain well with no evidence
inno _
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1979 1981
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Table I The relationship between estimated tumour size
(mean+s.e.), clinical stage and survival
Mean tumour volume
Group No. (ml)
Stage I-all 79 97+ 12
-alive NED 71 96+ 13
-dead 5 119+30
Stage II-all 31 213+49
-alive NED 23 183+47
-dead 8 300+133
Stage III & IV-all 7 129+24
0 1 2 3
Time (years)
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Figure 3 Actuarial survival for patients treated during two
different time intervals: 1970-1972 and 1979-1981. There were 29
patients in each group. P<0.01 (logrank).
of recurrence of either of their tumours. One patient, with
seminoma, was treated with further radiotherapy to the
para-aortic nodes; the other two patients had no treatment,
other than orchiectomy, for their second tumours.
The overall relapse rate in treated patients was 25/151
(16.5%). The cumulative time to relapse curve is shown in
Figure 4. The relapse rate in clinical stage I was 12/103
(11.7%) and in clinical Stage II. 11/41 (26.8%): chi-
squared=3.96; P<0.05. The relapse rate was 9/72 (12.5%)
in patients with primary tumours <100ml and 9/41 (22.0%)
in patients with primary tumours > 100ml. This apparent
difference is not statistically significant: chi-squared=1.108;
P>0.1.
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Table II The relationship between clinical stage, survival
and the interval between first symptom and first treatment
(mean+s.e.)
Mean symptom
Group No. duration (days)
Stage I-all 98 199+22
-alive NED 71 96+ 13
-dead 5 119+30
Stage 1I-all 40 189+29
-IIA 20 154+22
-IIB, IIC 20 225+51
-alive NED 30 169+22
-dead 10 250+ 102
Stage III & IV 8 176+87
There were no statistically significant differences between the
groups.
The average interval between first symptom and first
treatment was 198 + 17 days (range 11-1084). The
relationship between duration of symptoms before treatment,
survival, and clinical stage is shown in Table II. Once again
there were no significant differences between groups. The
mean interval between diagnosis and first treatment was
32±2 days.
The relationship between tumour size at diagnosis and
duration of symptoms for patients who had symptoms for
less than a year before treatment is shown in Figure 5. There
were 17 patients who had symptoms for more than a year
before treatment. The average size of primary tumour in this
group was 224ml. For patients with clinical stage I
seminoma and tumours <75 ml the mean duration of
symptoms was 199 +31 days; for patients with stage I
seminoma and tumours >75 ml the mean duration of
symptoms was 256+ 50 days.
Two patients had elevated levels of,HCG at diagnosis.
n)r %
Figure 4 Cumulative time to relapse curve for the 23 patients in
clinical stages I and II who relapsed after initial therapy.
The relapse rate according to the T-stage of the primary
tumour was 5/59 (8.5%) for TI primary tumours and 11/48
(23.0%) for T> 1 primary tumours: chi-squared =3.27;
P>0.05. In early stage (I and IIA) seminomas the relapse
rate was 9/49 (18.4%) for patients with TI primary tumours
as opposed to 13/39 (33.3%) for patients with primary
tumours T > 1: chi-squared = 1.85; P>0.05.
The relapse rates in Stage I seminoma according to the
interval between first symptom and first treatment are as
follows: interval > 1 year, 3/16 (19%); interval _ I year,
10/87 (11.5%); chi-squared=0.155; P=0.7.
The average size of the primary tumour was 129+16ml
(range 0.5-1150). The relationship between clinical stage,
survival, and size of the primary tumour is shown in Table I.
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Figure 5 The relationship between tumour size (mean+s.e.),
and duration of symptoms before first treatment.
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One patient, clinical stage IIB, remains well after
radiotherapy. The other patient who presented with Stage IV
disease and p HCG >100,000 died from respiratory failure
15 days after starting treatment with cis-platinum, bleomycin
and vinblastine. Only one patient had elevated AFP at
diagnosis. This fell, post orchiectomy, with a serum half-life
of 6 days. A review of the histology failed to show any
features of teratoma. He remains well three years after
radiotherapy.
The serum LDH at diagnosis was 321+17JUl1 in
patients with stage I disease and 533 + 117 IU 1 1 in patients
with stage II disease. LDH was estimated at diagnosis in
only two patients with advanced (Stage II or IV) disease, the
level was grossly elevated in both patients.
There are few data on tumour marker levels at the time of
relapse. None of the four patients who had AFP measured
had elevated levels; similarly none of the three patients who
had BHCG measured had elevated levels. Six patients had
serum LDH measured at relapse: in three the levels were
elevated, in three they were normal.
The major morbidity from treatment is summarised in
Table III. In addition to the data summarised in Table III
the following late complications have been observed.
Individual patients treated with abdominal irradiation
suffered from: lower limb ischaemia; myocardial infarction;
large bowel stricture (post-radiation fibrosis); diverticular
disease; gluten sensitive enteropathy; depression/alcohol
abuse. Individual patients treated with radiotherapy above
and below the diaphragm developed: pulmonary fibrosis;
acute cholecystitis; large bowel fibrosis/stricture. As with any
analysis of possible complications of treatment it is difficult
to be certain which of these various problems can be directly
attributed to the radiotherapy.
Table III The morbidity from radiotherapy in clinical
Stages I and II
Complication No.
Abdominal irradiation alone Ill
Early
Marrow depression 2
Severe nausea and vomiting I
Deep venous thrombosis I
Late
Duodenal ulcer 4
Proven infertility 3
Hypertension 2
Decreased libido 2
Chronic diarrhoea 4
Irradiation above and below the diaphragm 32
Early
Marrow depression 4
Dysphagia I
Lhermittes sign I
Late
Proven infertility 2
Renal impairment 2
Discussion
This study, based on patients seen and treated at a regional
centre, is free from many of the biases which intrude when
the experience of other centres is analysed. Patients are
referred to the Edinburgh department simply because of
where they live and not because they have advanced disease
or present especially difficult problems in management. The
low proportion of patients with stage III or IV disease (5.3%)
is similar to that in several other large studies (Calman et al.,
1979; Schultz et al., 1984; Thomas et al., 1982).
A striking, and gratifying, improvement in prognosis
occurred between the earlier and latter years of the study
period. The overall actuarial 5-year survival increased from
64.8% to 96.6%. There. was no obvious explanation for this
change. The introduction of lymphography in 1972-1973
seems, perhaps misleadingly, to have been associated with an
improvement in prognosis. Patients assigned to clinical Stage
I without having had lymphography had a long term
survival rate of 79.2%; patients in clinical Stage I who had
lymphography had a long term survival rate of 96.6%.
Understaging, due to omission of lymphography, cannot
entirely explain the improvement in prognosis since the para-
aortic nodes, the site of undetected disease, were irradiated
in all patients. Lymphography might have increased the
effectivenes of the radiotherapy by improving its localization,
but none of the patients who died from Stage I seminoma
relapsed in the para-aortic nodes.
Changes in the distribution by stage within the group of
patients with seminoma will not improve the survival of the
group as a whole; even though they might improve survival
within each clinical stage. If, because of some shift in
histological criteria, there is a change in the proportion of
seminomas in patients with germ-cell tumours then this
could affect prognosis for all patients with seminomas
(Oliver et al., 1984). In Edinburgh between 1970 and 1973
seminomas accounted for 46/76 (60.5%) of all germ-cell
tumours; between 1978 and 1981 52/114 (45.6%) of germ-cell
tumours were seminomas (chi-squared =3.48; P>0.05).
Although not achieving statistical significance, this change in
histological distribution might account for the improved
prognosis after 1978.
The availability of effective therapy for metastatic disease
has transformed the overall prognosis for patients with non-
seminomatous germ-cell tumours (NSGCT) (Einhorn &
Williams, 1980; Newlands et al., 1983). This factor is of less
importance for seminomas. Very few patients present with,
or develop, haematogenous metastases. Certainly the
improved prognosis in Edinburgh cannot be explained by
improvements in therapy for disseminated disease: only three
patients were treated with cis-platinum chemotherapy.
Analysis of national data from the USA failed to show any
improvement in survival for patients with seminoma between
1973-76 and 1976-79 (Li et al., 1982). The survival rate was
92% during both periods.
The T-stage of the primary tumour affected prognosis:
patients with tumours beyond TI had a significantly lower
long term survival (Figure 2). Advanced T-stage of the
primary tumour might signal the biologically more aggressive
tumours. Unfortunately T-stage takes no account of other
possible harbingers of aggressive tumour behaviour such as
vascular invasion (Sandeman & Matthews, 1979).
The results of prophylactic radiotherapy for adequately
staged patients with clinical Stage I disease are excellent:
96.11% long term survival overall; 100% survival for
patients with TI primary tumours. These results are achieved
without excessive morbidity. The relatively high incidence of
duodenal ulcer in patients treated for seminoma is puzzling
and has been noted by others (Peckham et al., 1985). We
have not observed the problem in patients treated with
similar radiation fields but higher dose, for non-
seminomatous tumours (Duncan & Munro, 1985).
No attempt was made routinely to assess fertility after
treatment. A total of 5 patients had proven infertility: the
true number is almost certainly higher. The radiation dose to
the remaining testis can, by extra shielding, be reduced below
the levels achieved in this study (Kubo & Shipley, 1982) with
consequent improvement in the fertility rate after treatment.
Second testicular primary tumours were relatively
frequent: 4/152 (2.6%). This represents a relative risk of
x500 compared with the normal male population, similar
findings have been described in a larger series (Hay et al.,
1984). This is in contrast to patients with NSGCT where
there is no apparent excess of second testicular tumours
(Duncan & Munro, 1985).
The results of radiotherapy for patients in clinical stages
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of 66% for patients with Stage II disease is inferior to that
which now can be expected for patients with clinical Stage II
NSGCT treated by combination chemotherapy. In common
with others (Thomas et al., 1982) we find no evidence to
support the concept of prophylactic irradiation above the
diaphragm for patients with Stage I or Stage II disease.
Radiotherapy to the mediastinum and supraclavicular nodes
does not completely prevent relapse at these sites, can only
benefit a small minority of patients, and significantly adds to
morbidity.
Effective chemotherapy is now available for disseminated
seminoma (Schuette et al., 1985; Peckham et al., 1985). In
the study from the Royal Marsden Hospital (Peckham et al.,
1985) 40/44 (91%) of patients treated with chemotherapy for
advanced seminoma are alive and disease-free 12 to 73
months after treatment. This raises the possibility of
omitting routine prophylactic radiotherapy to the retro-
peritoneum for patients with stage I seminoma and relying
on chemotherapy to treat those patients who subsequently
relapse. If a policy of surveillance after orchiectomy is to be
considered for patients with Stage I seminoma then the
identification of factors influencing relapse becomes as
relevant as finding factors which affect survival.
The relapse rate was significantly higher in clinical Stage
II compared with clinical Stage I. Tumour size at diagnosis
or duration of symptoms before treatment had little effect on
relapse rate. The T-stage of the primary tumour appeared to
affect relapse rate but the difference did not quite achieve
statistical significance. This is probably due to a Type II
statistical error: too few patients at risk in either group.
It is now considered reasonable not to treat the
retroperitoneum prophylactically in patients with Stage I
NSGCT and enter these patients in surveillance studies
(Peckham et al., 1983; Read et al., 1983). The arguments
used to support such a policy cannot simply be translated to
justify a similar policy for Stage I seminomas. Seminomas
are different in their biology and natural history from
NSGCT. The most serious defect in any argument in favour
of a policy of surveillance for Stage I seminoma is the lack
of adequate tumour markers for the tumour. Lactate
dehydrogenase levels correlate roughly with the amount of
tumour present but the enzyme is in no way a specific
monitor of disease activity. Placental alkaline phosphatase,
particularly when detected using the monoclonal antibody
H17E2, may prove a useful marker for seminoma but raised
marker levels in patients who smoke cloud the issue (Tucker
et al., 1985; Epenetos et al., 1985).
Data from studies of surveillance in patients with Stage I
seminoma are preliminary, the follow-up is short since most
of these studies only started in 1982 or 1983. The relapse
rate with surveillance for Stage I seminoma is probably
between 10 and 15%. Most of the surveillance studies
exclude patients with primary tumours that are T3 or T4 and
the patients in these studies have usually been staged with
lymphography and CT scanning. It is not possible to make a
direct comparison between patients in studies of surveillance
and all 103 patients with stage I seminoma in the Edinburgh
series. The group in the Edinburgh series which most closely
approximates the type of patient being entered into studies
of surveillance is the group of 38 patients with TI tumours
who had had lymphography. The 5-year survival in this
group was 100%; the relapse rate was 2/38 (5.15%). Recent
data from Toronto show that patients with Stage I
seminoma, whose staging investigations included lympho-
graphy and CT scanning, have a relapse rate of 2/150 (1.3%)
after prophylactic radiotherapy to the para-aortic nodes
(Thomas, 1985).
The data on tumour size at diagnosis (Table I) suggest
that patients with Stage II disease have larger primary
tumours than patients in clinical stages I, III or IV. It might
be that there are two subpopulations of seminomatous
tumours. One type is a tumour which metastasizes early,
hence the relatively small size of the primary tumour in
Stages III and IV. The other type is a tumour which grows
slowly and metastasizes later in its course, hence the larger
size of primary tumour in Stage II compared to Stage I.
We are unable to confirm the findings of Bosl et al. (1981)
that the longer the interval between first symptom and
diagnosis then the more advanced is the clinical stage of the
tumour. Bosl's study included both patients with seminoma
and those with non-seminomatous tumours. It may be that
delay in treatment only correlates with more advanced
disease for patients with non-seminomatous tumours:
tumours known to have higher metastatic potential and
shorter doubling times than seminomas.
The relationship between tumour size and the duration of
symptoms is complex (Figure 4). There is a paradoxical
decrease in the size of the primary tumour for patients with
symptom duration of more than 110 days before treatment.
It is difficult to know whether this apparent decrease is real
or artefactual: if it is real it is hard to explain.
The results from Edinburgh show that prophylactic
retroperitoneal irradiation, using the fields and dose
described, produces excellent survival for properly staged
patients with Stage I seminoma. We accept that many
patients, who do not have micro-metastatic disease in the
retroperitoneum, are being treated unneccessarily.
Nevertheless, the morbidity of treatment is low enough, and
the overall survival high enough, to justify such a policy.
The few patients who relapse can be effectively treated with
chemotherapy.
Our current recommendations for the management of
patients with seminoma, after inguinal orchiectomy and high
cord section, are as follows. Patients in clinical Stage I
should routinely have radiotherapy to the retroperitoneal
nodes. Patients in clinical Stages IIC, III or IV should be
treated with combination chemotherapy using a regime
based upon cis-platinum. The decision is more difficult for
patients in clinical Stage IIA or IIB. Chemotherapy will cure
about 90% of such patients (Peckham et al., 1985) but at a
high price in terms ot toxicity. Radiotherapy to the
retroperitoneal nodes will cure approximately 80% of such
patients and its toxicity is less than that of chemotherapy.
The 20% who are not cured by radiation therapy will
require salvage chemotherapy. On balance, a policy of initial
treatment with radiotherapy can be justified for patients with
Stage IIA or IIB disease; as chemotherapy for seminoma
becomes less toxic this balance may change in favour of
initial treatment with cytotoxic drugs.
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